A school-based, prospective, cohort study was conducted to evaluate the epidemiology of P. falciparum (Pf) infections in school-age children and determine the impact of the screen-and-treat approach on Pf infection and anemia prevalence among students in two different transmission settings. Investigators aimed to evaluate how frequently malaria rapid diagnostic tests (mRDTs) fail to detect low-parasite-density infections as well as whether low-density infections contribute to the burden and health consequences of Pf infection in school-age children and whether they contain gametocytes, the parasite stage required for transmission from humans to mosquitos.
Students were enrolled in four schools in southern Malawi in the rainy (March-May) and dry season (Sept-Nov) of 2015. 15 students per grade-level (grades 1-8), were invited to participate. Following enrollment, students were evaluated at baseline for screening-and-treatment, and followed-up 1, 2 and 6 weeks later. At each follow-up visit, a blood sample was obtained for microscopy and molecular detection of parasites and students were interviewed about bed net use the night prior, current or recent illness, and use of antimalarial treatment. At the final visit, a mRDT and hemoglobin test were repeated, and parents were interviewed and portable medical records ("health passports") were reviewed to identify intercurrent fever or malaria treatment.
Study Type
OBSERVATIONAL
Enrollment
786
Students were screened by mRDTs and treated with artemether-lumefantrine if positive
P. falciparum infection
Any stage Pf infection detected by quantitative polymerase chain reaction (PCR)
Time frame: 6 weeks after screening
P. falciparum gametocyte presence
Pfs25 quantitative reverse transcriptase PCR
Time frame: 6 weeks after screening
P. falciparum gametocyte density
Pfs25 quantitative reverse transcriptase PCR
Time frame: 6 weeks after screening
Microscopic P. falciparum infection
Pf infection detected by microscopy
Time frame: 6 weeks after screening
Anemia
Hb measured by Hemocue and categorized using WHO age and gender specific values
Time frame: 6 weeks after screening
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.